Literature DB >> 29221296

Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy.

Chen-Sung Lin1,2,3,4, Chao-Yu Liu1,4,5, Chih-Tao Cheng6,7, Yu-Chen Tsai8, Lun-Wei Chiou9, Ming-Yuan Lee10, Chia-Chuan Liu1,4, Chih-Hsun Shih1,4.   

Abstract

BACKGROUND: The objective of this study was to appraise the prognostic role of initial pan-endoscopic tumor length at diagnosis within or between operable esophageal squamous cell carcinoma (ESCC) undergoing upfront esophagectomy or neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by esophagectomy.
METHODS: Between Jan 2001 and Dec 2013 in Koo-Foundation Sun Yat-sen Cancer Center in Taiwan, 101 ESCC patients who underwent upfront esophagectomy (surgery group) and 128 nCCRT followed by esophagectomy (nCCRT-surgery group) were retrospectively collected. Prognostic variables, including initial pan-endoscopic tumor length at diagnosis (sub-grouped ≤3, 3-5 and >5 cm), status of circumferential resection margin (CRM), and pathological T/N/M-status and cancer stage, were appraised within or between surgery and nCCRT-surgery groups.
RESULTS: Within surgery group, longer initial pan-endoscopic tumor length at diagnosis (≤3, 3-5 and >5 cm; HR =1.000, 1.688 and 4.165; P=0.007) was an independent prognostic factor that correlated with advanced T/N/M-status, late cancer stage, and CRM invasion (all's P<0.001). Based on the initial pan-endoscopic tumor length at diagnosis ≤3, 3-5 and >5 cm, nCCRT-surgery group had a poorer (P=0.039), similar (P=0.447) and better (P<0.001) survivals than did surgery group, respectively. For those with initial pan-endoscopic tumor length at diagnosis >5 cm, nCCRT-surgery group had more percentage of T0/N0-status and stage 0 (all's P<0.05), and fewer rate of CRM invasion (P=0.036) than did surgery group.
CONCLUSIONS: Initial pan-endoscopic tumor length at diagnosis could be a criterion to select proper ESCC cases for nCCRT followed by esophagectomy to improve survival and reduce CRM invasion.

Entities:  

Keywords:  Circumferential resection margin (CRM); esophageal squamous cell carcinoma (ESCC); prognosis; tumor length

Year:  2017        PMID: 29221296      PMCID: PMC5708394          DOI: 10.21037/jtd.2017.08.108

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  40 in total

Review 1.  The society of thoracic surgeons guidelines on the diagnosis and staging of patients with esophageal cancer.

Authors:  Thomas K Varghese; Wayne L Hofstetter; Nabil P Rizk; Donald E Low; Gail E Darling; Thomas J Watson; John D Mitchell; Mark J Krasna
Journal:  Ann Thorac Surg       Date:  2013-06-07       Impact factor: 4.330

2.  The prognostic value of circumferential resection margin in esophageal squamous cell carcinoma after concurrent chemoradiation therapy and surgery.

Authors:  Chao-Yu Liu; Bing-Yen Wang; Ming-Yuan Lee; Yu-Chen Tsai; Chia-Chuan Liu; Chih-Hsun Shih
Journal:  J Chin Med Assoc       Date:  2013-08-12       Impact factor: 2.743

3.  Prognosis of Patients With Pathologic T0 N+ Esophageal Squamous Cell Carcinoma After Chemoradiotherapy and Surgical Resection: Results From a Nationwide Study.

Authors:  Yin-Kai Chao; Hui-Shan Chen; Bing-Yen Wang; Po-Kuei Hsu; Chia-Chuan Liu; Shiao-Chi Wu
Journal:  Ann Thorac Surg       Date:  2016-02-22       Impact factor: 4.330

4.  Effectiveness of neoadjuvant chemoradiotherapy for early-stage esophageal cancer.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Ate van der Gaast
Journal:  J Clin Oncol       Date:  2014-12-01       Impact factor: 44.544

5.  Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status.

Authors:  Mohamad A Eloubeidi; Renee Desmond; Miguel R Arguedas; Carolyn E Reed; C Mel Wilcox
Journal:  Cancer       Date:  2002-10-01       Impact factor: 6.860

Review 6.  Preoperative evaluation of lymph node metastasis in esophageal cancer.

Authors:  Yoko Murata; Masaho Ohta; Kazuhiko Hayashi; Hiroko Ide; Ken Takasaki
Journal:  Ann Thorac Cardiovasc Surg       Date:  2003-04       Impact factor: 1.520

7.  Malignant esophageal strictures: staging accuracy of endoscopic ultrasonography.

Authors:  M F Catalano; J Van Dam; M V Sivak
Journal:  Gastrointest Endosc       Date:  1995-06       Impact factor: 9.427

8.  The Prognostic Impact of Preoperative and Postoperative Chemoradiation in Clinical Stage II and III Esophageal Squamous Cell Carcinomas: A Population Based Study in Taiwan.

Authors:  Hui-Shan Chen; Shiao-Chi Wu; Po-Kuei Hsu; Chien-Sheng Huang; Chia-Chuan Liu; Yu-Chung Wu
Journal:  Medicine (Baltimore)       Date:  2015-06       Impact factor: 1.889

Review 9.  Epidemiologic differences in esophageal cancer between Asian and Western populations.

Authors:  Han-Ze Zhang; Guang-Fu Jin; Hong-Bing Shen
Journal:  Chin J Cancer       Date:  2012-04-13

10.  Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma.

Authors:  Yoshinori Fujiwara; Reigetsu Yoshikawa; Norihiko Kamikonya; Tsuyoshi Nakayama; Kotaro Kitani; Masanori Tsujie; Masao Yukawa; Johji Hara; Takehira Yamamura; Masatoshi Inoue
Journal:  Mol Clin Oncol       Date:  2013-05-21
View more
  2 in total

1.  Pan-endoscopic tumor length as the marker to predict response to neoadjuvant therapy for ESCC warrants additional investigation.

Authors:  Yu-Feng Deng; Tian-Zhu Yuan
Journal:  J Thorac Dis       Date:  2018-04       Impact factor: 2.895

2.  Mediastinoscopy-assisted esophagectomy for T2 middle and lower thoracic esophageal squamous cell carcinoma patients.

Authors:  Jun Wang; Ning Wei; Yimin Lu; Xiaoying Zhang; Nanqing Jiang
Journal:  World J Surg Oncol       Date:  2018-03-16       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.